With the development of PSMA-617 showing an improved and fast kidney excretion, a highly promising compound is already being clinically investigated for endoradiotherapy of prostate cancer with 177Lu or 225Ac [15,16,17]. Here, FOLH1 is linked to prostate carcinoma.